MX2022004934A - Metodos para tratar un cancer. - Google Patents

Metodos para tratar un cancer.

Info

Publication number
MX2022004934A
MX2022004934A MX2022004934A MX2022004934A MX2022004934A MX 2022004934 A MX2022004934 A MX 2022004934A MX 2022004934 A MX2022004934 A MX 2022004934A MX 2022004934 A MX2022004934 A MX 2022004934A MX 2022004934 A MX2022004934 A MX 2022004934A
Authority
MX
Mexico
Prior art keywords
methods
treating cancer
slfn11
dna
patients
Prior art date
Application number
MX2022004934A
Other languages
English (en)
Inventor
Elisabetta Leo
Claudia Winkler
Mark James O''CONNOR
Gemma Nicole Jones
Andrew James Pierce
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of MX2022004934A publication Critical patent/MX2022004934A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • Reproductive Health (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

En el presente documento se divulgan métodos para tratar un cáncer con una combinación de un inhibidor de WEE1 y un agente que daña el ADN en pacientes que tienen células cancerosas deficientes en SLFN11.
MX2022004934A 2019-10-25 2020-10-23 Metodos para tratar un cancer. MX2022004934A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962926055P 2019-10-25 2019-10-25
PCT/EP2020/079856 WO2021078925A1 (en) 2019-10-25 2020-10-23 Methods of treating cancer

Publications (1)

Publication Number Publication Date
MX2022004934A true MX2022004934A (es) 2022-05-16

Family

ID=73030090

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022004934A MX2022004934A (es) 2019-10-25 2020-10-23 Metodos para tratar un cancer.

Country Status (12)

Country Link
US (1) US20220387468A1 (es)
EP (1) EP4048277A1 (es)
JP (1) JP2022554157A (es)
KR (1) KR20220088896A (es)
CN (1) CN114599399A (es)
AU (1) AU2020369996A1 (es)
BR (1) BR112022007609A2 (es)
CA (1) CA3158274A1 (es)
IL (1) IL292348A (es)
MX (1) MX2022004934A (es)
TW (1) TW202131925A (es)
WO (1) WO2021078925A1 (es)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR060635A1 (es) 2006-04-27 2008-07-02 Banyu Pharma Co Ltd Derivados de 1,2-dihidro-3h-pirazolo[3,4-d]pirimidin-3-ona, composiciones farmaceuticas que los comprenden y su uso en el tratamiento del cancer
US8198281B2 (en) 2007-04-25 2012-06-12 Merck Sharp & Dohme Corp. Crystalline forms of dihydropyrazolopyrimidinone
HUE032403T2 (en) 2007-06-15 2017-09-28 Msd Kk Bicycloaniline derivative
SI2477628T1 (sl) 2009-09-15 2014-11-28 Merck Sharp & Dohme Corp. Priprava oblik kristalinskega hemihidrata dihidropirazolopirimidinona
WO2018183891A1 (en) * 2017-03-31 2018-10-04 Cascadian Therapeutics Combinations of chk1- and wee1 - inhibitors
US20200171082A1 (en) * 2017-06-20 2020-06-04 Nantomics, Llc Quantifying slfn11 protein for optimal cancer therapy

Also Published As

Publication number Publication date
EP4048277A1 (en) 2022-08-31
JP2022554157A (ja) 2022-12-28
BR112022007609A2 (pt) 2022-07-19
TW202131925A (zh) 2021-09-01
WO2021078925A1 (en) 2021-04-29
KR20220088896A (ko) 2022-06-28
AU2020369996A1 (en) 2022-06-02
CA3158274A1 (en) 2021-04-29
IL292348A (en) 2022-06-01
CN114599399A (zh) 2022-06-07
US20220387468A1 (en) 2022-12-08

Similar Documents

Publication Publication Date Title
BR112021022812A2 (pt) Dosagem de inibidor de kras para tratamento de cânceres
PH12020551923A1 (en) Methods and compositions for treating cancer
PH12021500004A1 (en) Pd-1/pd-l1 inhibitors
MX2018004599A (es) Terapia de combinacion para el tratamiento de neoplasias malignas.
AU2018372763A1 (en) Materials and methods for treatment of autosomal dominant Retinitis Pigmentosa
CL2018000943A1 (es) Terapia de combinación para tratar tumores malignos
MX2022006701A (es) Terapia combinada para el tratamiento de neoplasias malignas.
WO2017177179A9 (en) Compositions and methods for treating cancer, inflammatory diseases and autoimmune diseases
ZA201803162B (en) Combination therapy for treating malignancies
MX2015013177A (es) Combinacion de tratamientod de cancer usando microarns e inhibidores de egfr-tki.
MX2020011684A (es) Inhibicion combinada de pd-1/pd-l1, tgfbeta y dna-pk para el tratamiento del cancer.
MX2020001727A (es) Terapia de combinacion.
MX2019013862A (es) Terapia de combinacion.
MX2023000549A (es) Combinaciones para el tratamiento de neoplasias usando localizacion de celulas quiescentes e inhibidores de egfr.
MX2021000847A (es) Procedimientos para el tratamiento del cancer con el inhibidor de pi3k, gdc 0077.
MX2022008208A (es) Terapia de combinación que comprende inhibidores de a2a/a2b y proteína de muerte programada 1 /ligando de muerte programada 1 (pd-1/pdl1).
WO2018102687A3 (en) Combination therapy for treating cancer
MX2019002108A (es) Terapia de combinacion con inhibidores de glutaminasa.
MX2022010977A (es) Inhibidores de egfr, kras, braf y otros objetivos y uso de los mismos.
PH12019500758A1 (en) Pharmaceutical compositions and methods for the treatment of cancer
JO3262B1 (ar) توليفة من ديسيتابين مع مثبط سيتيدين دي أميناز واستخدامها في علاج السرطان
MX2023001425A (es) Inhibidores de cinasa de insercion proviral en linfomas murinos (pim) para el tratamiento de neoplasias mieloproliferativas y fibrosis asociadas con cancer.
BR112022008295A2 (pt) Inibição combinada de pd-1, tgfbeta e tigit para o tratamento de câncer
MX2020008881A (es) Métodos de tratamiento contra el cáncer que comprenden inhibidores de chk1.
EP3946297A4 (en) HYALURONIC ACID NANOPARTICLES COMPRISING NADPH OXIDASE INHIBITORS AND THEIR USES IN THE TREATMENT OF CANCER